DaVita Inc. (NYSE:DVA) released its 2025 Form 10‑K on May 4, 2026, reporting operating income of $2.044 billion and adjusted operating income of $2.094 billion—a 5.7% increase from the $1.981 billion reported in 2024. Adjusted earnings per share rose 11.4% to $10.78 from $9.68 in 2024, reflecting disciplined cost management and a favorable mix of high‑margin services.
Operating cash flow reached $1.887 billion and free cash flow $1.024 billion, underscoring the company’s ability to generate liquidity while investing in growth. DaVita returned $1.788 billion to shareholders through share repurchases of 12.679 million shares, cutting the outstanding share count by 14.9% and reinforcing its commitment to capital allocation.
The filing highlighted several strategic initiatives. DaVita completed a Brazil acquisition that expands its presence in Latin America, reinforcing its international footprint. The Integrated Kidney Care (IKC) program continued to perform strongly, supporting the company’s shift toward value‑based care. A review of an April 2025 cybersecurity incident was included; the company said the event was contained without disrupting patient care.
Operating margin stood at 15.3% for 2025, a slight decline from 15.5% in 2024, but still robust in the face of rising cost inflation. Management noted that “Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment. Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond.”
DaVita guided for fiscal 2026 earnings per share of $13.60–$15.00, maintaining a stable outlook amid a competitive dialysis market. Analysts had expected Q1 2026 earnings of $2.41 per share and revenue of $3.30 billion; the company’s guidance signals confidence in sustaining growth while managing headwinds such as pricing pressure and cost inflation.
The market reaction to the 2025 results was modest; shares slipped 0.38% in after‑hours trading, reflecting concerns about the April 2025 cybersecurity incident and a severe flu season that weighed on U.S. treatment volumes. Nonetheless, the company’s strong cash generation and share‑repurchase program were viewed positively by investors seeking long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.